Newly released data presented by Teva Pharmaceuticals at the Psych Congress Elevate 2025 highlights substantial rates of undertreated Tardive Dyskinesia (TD) in long-term care settings. This neurological disorder, often resulting from long-term use of antipsychotic medications, remains a significant challenge due to its debilitating involuntary movements. The study reveals that despite available treatments, many patients with Tardive Dyskinesia in long-term care facilities are not receiving adequate intervention, pointing to a critical gap in healthcare practice. Teva’s findings underscore the urgent need for enhanced awareness and proactive treatment strategies to improve the quality of life for affected individuals. With a focus on healthcare improvement, these insights call for medical practitioners and caregivers to prioritize timely diagnosis and treatment of TD. The showcased research at Psych Congress 2025 aims to stimulate further discussion and action towards better management of neurological disorders within vulnerable populations.
GlobeNewswireNew data shows Halifax traffic congestion is worst on Thursdays, among the worst in Canada
April 28, 2026
Halifax is experiencing one of the most severe traffic congestion issues in Canada, with new data indicating that Thursdays are particularly problematic for commuters. The